Swedish Orphan Biovitrum AB (publ) (BIT:1SOBI)

Market Cap	10.64B
Revenue (ttm)	2.52B
Net Income (ttm)	1.18M
Shares Out	n/a
EPS (ttm)	0.00
PE Ratio	9,051.83
Forward PE	17.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	130
Average Volume	75
Open	30.52
Previous Close	30.28
Day's Range	29.34 - 30.80
52-Week Range	22.64 - 37.72
Beta	n/a
RSI	45.46
Earnings Date	Feb 5, 2026

About BIT:1SOBI

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1939
• Employees: 1,806
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1SOBI

Financial Performance

In 2024, BIT:1SOBI's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK